Journal home > Archive > Table of Contents > News and Views >Abstract

Journal home Advance online publication Current issue Archive Press releases Supplements Focuses Guide to authors Online submission For referees Free online issue Contact the journal Subscribe Advertising work@npg Reprints and permissions About this site For librarians   NPG Resources Nature Nature Reviews Nature Immunology Nature Cell Biology Nature Genetics news@nature.com Nature Conferences Dissect Medicine NPG Subject areas Biotechnology Cancer Chemistry Clinical Medicine Dentistry Development Drug Discovery Earth Sciences Evolution & Ecology Genetics Immunology Materials Science Medical Research Microbiology Molecular Cell Biology Neuroscience Pharmacology Physics Browse all publications News and Views Nature Medicine - 12, 881 - 882 (2006) doi:10.1038/nm0806-881 Targeted cancer therapeutics: the heartbreak of success Douglas L Mann The author is in the Winters Center for Heart Failure Research, Section of Cardiology, Department of Medicine, Baylor College of Medicine and the Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77030, USA. dmann@bcm.tmc.edu kanjiTyrosine kinase inhibitors, widely hailed for their success as treatments for cancer, are also plagued by the issue of cardiotoxic side effects. The mechanism behind the heart damage now comes to light for one such inhibitor, imatinib mesylate, also known as Gleevec (pages 908–916). MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated. RESEARCH Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nature Medicine Article (01 Aug 2006) In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' Nature Medicine Correspondence (01 Jan 2007) In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' Nature Medicine Correspondence (01 Jan 2007) In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' Nature Medicine Correspondence (01 Jan 2007) See all 7 matches for Research  Top Abstract Previous | Next Table of contents Full text Download PDF Send to a friend Rights and permissions Order commercial reprints CrossRef lists 4 articles citing this article Save this link Figures & Tables See also: Article by Kerkelä et al. Export citation Open Innovation Challenges Direct Molecular Detection of Proteins and Nucleic Acids Deadline: Dec 02 2009 Reward: $5,000 USD This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id... Single-cell Analysis Platform Deadline: Dec 02 2009 Reward: $5,000 USD This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is... More Challenges Powered by: nature jobs Senior DMPK scientist Cancer Research Technology (CRT) London, United Kingdom Faculty Positions in Cancer, Cardiovascular and Metabolic Diseases, Immunology Institut de recherches cliniques de Montreal Montreal, Quebec, Canada More science jobs Post a job for free Search buyers guide:

ISSN: 1078-8956 EISSN: 1546-170X Journal home | Advance online publication | Current issue | Archive | Press releases | Supplements | Focuses | For authors | Online submission | For referees | Free online issue | About the journal | Contact the journal | Subscribe | Advertising | work@npg | Reprints and permissions | About this site | For librarians

©2006 Nature Publishing Group | Privacy policy